Glaukos Corporation (GKOS) Analysts See $-0.12 EPS

April 26, 2018 - By Louis Casey

Glaukos Corporation (NYSE:GKOS) Logo

Analysts expect Glaukos Corporation (NYSE:GKOS) to report $-0.12 EPS on May, 2.They anticipate $0.14 EPS change or 700.00 % from last quarter’s $0.02 EPS. After having $0.03 EPS previously, Glaukos Corporation’s analysts see -500.00 % EPS growth. The stock increased 2.91% or $0.89 during the last trading session, reaching $31.52. About 263,962 shares traded. Glaukos Corporation (NYSE:GKOS) has declined 40.30% since April 26, 2017 and is downtrending. It has underperformed by 51.85% the S&P500.

Glaukos Corporation (NYSE:GKOS) Ratings Coverage

Among 6 analysts covering Glaukos (NYSE:GKOS), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Glaukos had 13 analyst reports since November 8, 2017 according to SRatingsIntel. BMO Capital Markets maintained Glaukos Corporation (NYSE:GKOS) rating on Thursday, November 16. BMO Capital Markets has “Outperform” rating and $38 target. Stifel Nicolaus maintained the stock with “Buy” rating in Friday, February 23 report. The rating was maintained by Cantor Fitzgerald with “Buy” on Friday, March 23. The firm earned “Outperform” rating on Thursday, March 1 by BMO Capital Markets. The rating was downgraded by Stifel Nicolaus to “Hold” on Friday, April 13. The rating was maintained by Stifel Nicolaus with “Buy” on Monday, February 26. Wells Fargo maintained the stock with “Buy” rating in Tuesday, December 12 report. The firm has “Buy” rating given on Thursday, March 1 by Stephens. Cantor Fitzgerald maintained Glaukos Corporation (NYSE:GKOS) rating on Tuesday, November 7. Cantor Fitzgerald has “Buy” rating and $60.0 target. The firm has “Buy” rating by Piper Jaffray given on Wednesday, January 10.

Glaukos Corporation, an ophthalmic medical technology company, focuses on the development and commercialization of products and procedures designed to treat glaucoma. The company has market cap of $1.10 billion. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. It currently has negative earnings. The company's product pipeline includes iStent Inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry with the goal of achieving intraocular pressure reduction; iStent Supra suprachoroidal micro-bypass stent, which is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration.

Glaukos Corporation (NYSE:GKOS) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.